The NRF2 pathway activates a cell survival response when cells are exposed to xenobiotics or are under oxidative stress. Therapeutic activation of NRF2 can also be used prior to insult as a means of disease prevention. However, prolonged expression of NRF2 has been shown to protect cancer cells by inducing the metabolism and efflux of chemotherapeutics, leading to both intrinsic and acquired chemoresistance to cancer drugs. This effect has been termed the "dark side" of NRF2. In an effort to combat this chemoresistance, our group discovered the first NRF2 inhibitor, the natural product brusatol, however the mechanism of inhibition was previously unknown. In this report, we show that brusatol's mode of action is not through direct inhibition of the NRF2 pathway, but through the inhibition of both cap-dependent and cap-independent protein translation, which has an impact on many short-lived proteins, including NRF2. Therefore, there is still a need to develop a new generation of specific NRF2 inhibitors with limited toxicity and off-target effects that could be used as adjuvant therapies to sensitize cancers with high expression of NRF2.
| INTRODUCTION
Chemoresistance to current drug regimens for the treatment of cancer has become a major health concern leading to the usage of highly cytotoxic chemicals with many unwanted side effects. The molecular mechanisms that lead to chemoresistance are not well understood, resulting in the continued reliance on broad-spectrum, highly toxic chemotherapeutics. There are a number of potential avenues to combat chemoresistance. One is through personalized medicine, which would foster the development of highly-specific targeted therapies based on the molecular profile of each individual patient's cancer. This means that the treatment would be more effective in a shorter amount of time due to the decreased likelihood that chemoresistance may occur. A second approach would be to develop a better molecular understanding of the mechanisms underlying chemoresistance and develop adjuvant therapies to increase the efficacy of chemotherapeutics. 1 In order to address this second option for targeted therapy, we developed the first inhibitor of the nuclear factor-erythroid factor 2-related 2 (NRF2) pathway based on the discovery that high levels of NRF2 are associated with resistance to chemotherapeutics.
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NRF2 is a redox-sensitive transcription factor that maintains the crucial intracellular reductive/oxidative (redox) balance of the cell. To do so, it up-regulates genes that are involved in phase I and II drug metabolism, glutathione synthesis, and xenobiotic drug transport. 3 Because of the critical role played by NRF2 in cellular protection, timely activation by NRF2 is needed. As a result, NRF2 is constantly translated by the cell; however, under stress-free conditions, when NRF2 activation is not needed, its negative regulator KEAP1
constantly targets NRF2 for degradation. 4, 5 KEAP1 is a substrate adaptor protein that is part of an E3 ubiquitin ligase complex that polyubiquitylates NRF2 and targets it for degradation by the 26S proteasome. 4, 5 A critical cysteine residue in KEAP1, cysteine 151 (Cys151), can become oxidized or covalently modified by reactive oxygen species (ROS) or electrophiles, causing a conformational change in KEAP1, preventing polyubiquitylation, and subsequent degradation of NRF2. 6 Newly synthesized NRF2 then accumulates in the cytosol and translocates into the nucleus, where it forms a heterodimer with small MAF proteins, binds to an enhancer sequence, the antioxidant response element (ARE), in the promoter region of its target genes, and promotes the antioxidant response.
Early investigations determined that up-regulation of NRF2 with dietary phytochemicals (sulforaphane, cinnamaldehyde, etc.) could protect against cancer and other diseases, prompting the search for NRF2-inducing compounds. 7, 8 However, the recognition that certain cancers overexpress NRF2, either through somatic mutations or epigenetic silencing of key negative regulators, and that chronic upregulation of NRF2 can lead to tissue damage and cancer progression, led to the concept of the "dark side" of NRF2. 2, 3, 9 To overcome this "dark side," our lab identified the first NRF2 inhibitor, brusatol, and proved that inhibition of NRF2 sensitized non-small cell lung cancer (NSCLC) cells to cisplatin treatment, making combination therapy with an NRF2 inhibitor a promising new initiative for the treatment of cancer with high levels of NRF2. 10 While treatment with brusatol, a quassinoid compound extracted from Brucea javanica, was effective in the nanomolar range at inhibiting NRF2 signaling, the mode of action was unknown. 10 Despite this, brusatol was shown to be effective in enhancing the antitumor action of cisplatin in a mutant KRAS G12D-induced lung cancer model. 11 In the present study, the mode of action of brusatol as an NRF2 inhibitor was determined.
Brusatol was found to be a general translation inhibitor, which causes a decline in the protein levels of short-lived proteins, including NRF2. 
| Fluorescent brusatol probe
The Immunoaffinity (IAF) tag was synthesized as previously described. 
| Dual reporters for translation inhibition
The FF-Ren and FF-EMCV IRES-Ren plasmids were a kind gift from genes. The top 10 up-and down-regulated genes are shown in Table 1 .
Interestingly, when comparing the gene expression modulation of brusatol with other compounds, brusatol shared a similar gene-set enrichment pattern with the translation inhibitor cycloheximide (Fig. 1A) . A more indepth analysis revealed that brusatol and cycloheximide shared 1,339 upregulated and 1,320 down-regulated genes (Fig. 1B) . As a follow-up, brusatol was compared to ricin and puromycin, two other translation inhibitors with distinct mechanisms of action. Brusatol also showed a similar gene-set enrichment pattern to both inhibitors (Fig. 1C) . Gene-sets that were shared between brusatol and ricin (176 genes up-regulated and 175 down-regulated) (Fig. 1D ) or brusatol and puromycin (136 up-regulated and 110 down-regulated) (Fig. 1E ) treatment were found to be equally significant, considering that ricin and puromycin regulated a smaller subset of genes compared to cycloheximide. These results indicated that brusatol might function as a protein translation inhibitor. Additionally, RNA-seq profiling after brusatol treatment revealed a 0.6 fold increase in NRF2 mRNA transcript levels. This phenomenon likely occurs as a compensation for the rapid loss of the NRF2 protein, and has been previously reported. 15 
| Brusatol localizes to the endoplasmic reticulum
Given that the effects of brusatol treatment resembled that of other established protein translation inhibitors, we attempted to determine if brusatol co-localizes in the cell to a site of active translation. In order to do this, brusatol was chemically modified with a fluorescent immunoaffinity (IAF) tag to track its subcellular location using live cell fluorescent microscopy ( Fig. 2A) . Live cell images were acquired via deconvolution microscopy and the merged images between brusatol-IAF and the different organelle tracker dyes indicated that brusatol-IAF localized to the endoplasmic reticulum (ER) (Fig. 2C) . Treatment with non-tagged brusatol was used as a negative control, and no autofluorescence was observed.
| Inhibition of cap-dependent and cap-independent translation by brusatol
Since brusatol mimics the effects of other translation inhibitors and concentrates to the ER, the ability of brusatol to inhibit cap-dependent or cap-independent translation was measured. A549 cells were transfected with a plasmid that expresses mRFP under the control analyzed by live cell fluorescent microscopy ( Fig. 3B ) and Western blot (Fig. 3C) . However, rapamycin only inhibited the expression of mRFP without affecting GFP expression ( Fig. 3B and C) . In addition to GFP, the levels of the cap-dependent proteins NRF2 and p53, were shown to decrease with brusatol or CHX treatment (Fig. 3C) . Furthermore, the inhibitory effects of brusatol were quantified using the Firefly (FF) and Renilla (Ren) dual reporter constructs in A549 cells. In the FF-Ren construct, a T3 RNA polymerase promoter drives the expression of a (Fig. 3D and E) . Together, these results indicated that brusatol inhibits both cap-dependent and cap-independent translation. 
| Brusatol inhibits the expression of short-lived proteins
Having identified that brusatol localized to the ER and inhibited both cap-dependent and cap-independent protein translation, it was predicted that brusatol would affect short-lived endogenous proteins or other endogenous proteins that are constantly translated.
Therefore, the dose-dependent inhibitory effects of brusatol on NRF2, other short-lived proteins (p53 and p21), or long-lived proteins (the AAA+ chaperone p97 and GAPDH) were tested. 10, 17, 18 Bruceantin, another translation inhibitor with a chemical structure similar to
that of brusatol was also tested. After a 4 h treatment, both brusatol and bruceantin reduced the protein levels of NRF2, p53, and p21 in a dose-dependent manner, while the expression of p97 and GAPDH
were not affected ( Fig. 4A and B) . Taken together, these results indicate that brusatol inhibits NRF2 and other short-lived, constantly translated proteins through inhibition of protein translation.
| DISCUSSION
There is substantial evidence indicating that NRF2 up-regulation prevents cancer initiation, which has encouraged the development of and enhances the efficacy of cisplatin using the KRAS-G12D induced murine lung tumor model in vivo. 11 Given that it was the first of its class, we set out to elucidate the mechanism of action of brusatol in regulating NRF2 levels using A549 cells which have constitutively high NRF2 due to a mutation in KEAP1. 19 In this study, we identified brusatol as a potent inhibitor of protein translation. RNA-seq profiling was initially used to assess changes to the with the notion that brusatol may be an inhibitor of protein translation, early reports on brusatol and bruceantin claimed that these drugs inhibit the peptidyl transferase reaction in biochemical assays. [20] [21] [22] [23] Furthermore, a crystal structure of a partial ribosome bound to bruceantin was reported in 2009, and molecular footprinting data suggested that bruceantin binds to specific nucleotides within the A-site of the ribosome, some of which are conserved between eukaryotes, prokaryotes, and archaea. 24 Most recently, using a mass spectrometry profiling approach, it was reported that brusatol is an inhibitor of proteins with short half-lives. 25 An interesting feature of brusatol is that its EC 50 , the effective concentration in reducing NRF2 protein levels to 50%, is 40 nM in most cancer cell lines tested. However, previous studies performed in rabbit reticulocyte lysate utilized brusatol in micromolar concentrations. [20] [21] [22] [23] In order to address this finding, we also performed an in vitro transcription and translation assay and determined that brusatol inhibited translation in vitro with an EC 50 of 1 μM, consistent with previous reports (data not shown). The large discrepancy between effective doses in vitro may be due to the fact that brusatol concentrates to the ER following cellular uptake (Fig. 2C ). Moreover, a previous structure-activity relationship study indicates that the hydrophobic side chain of related quassinoids is responsible for their cellular uptake and retention, 20 29 However, a reduction in NRF2 mRNA and protein levels was also reported using doses of 5 and 10 µM, potentially indicating that there is either toxicity, or an effect on global protein translation associated with this compound, since inhibiting the NRF2-MAFG interaction should not affect NRF2 expression. 29 In summary, specific NRF2 inhibitors will be highly effective for overcoming chemoresistance in tumors with high levels of NRF2, which is a major obstacle for cancer therapy, and these drugs will have a substantial impact on the future treatment of NSCLC and other cancers with high levels of NRF2. | 1499
